// changes done below on July 01 2024 // till here on July 01 2024

Cell Line Development Market Revenue to Cross USD 4.5 Billion by 2035 | Roots Analysis

Published: March 2024


According to a recently published report by Roots Analysis, the growing cases of chronic diseases have led to an increase in the demand for biologics that require cell lines for the study of the efficacy of these biopharmaceutical products, which is anticipated to drive the market.

Global Cell Line Development Market Overview

The global cell line development market is anticipated to grow at a CAGR of 13.2% from 2023-2035, reaching USD 4.5 billion by 2035.

The growth of cell line development market is likely to be the result of growing prevalence of chronic diseases and increasing demand for biopharmaceuticals to treat patients. Cell line refers to the in-vitro production of cells extracted from single cells and maintained for a particular period. Currently, the biopharmaceutical companies are witnessing a rapid surge in the requirement of biologics to treat a broad range of chronic diseases. These cell lines play an essential role in the production of biologics such as cell based therapies, monoclonal antibodies and recombinant proteins. However, the production of cell lines is a challenging process and requires skilled labor that poses expertise in isolation, confirmatory analytics, transfection, cell characterization and purification of cell lines. In order to address these concerns, several researchers are exploring advanced technologies to boost the production of cell lines. Driven by ongoing research on biopharmaceuticals and cell line development, it is anticipated that the market will witness substantial growth in the upcoming years.

The 223-page report contains a detailed Table of Contents on the " Cell Line Development Market," Type of Deployment, Type of Delivery, Features of Software, and Global Forecasts, 2023-2035" here: https://www.rootsanalysis.com/reports/cell-line-development-market.html

Market Drivers

The cell line development market is expected to receive significant growth during the forecast period due to several factors. Some of the promising factors include the growing prevalence of biopharmaceutical products such as recombinant proteins, monoclonal antibodies, and vaccines for the treatment of various diseases. Additionally, the ongoing technological advancements to improve the cell line development process are the most promising driver, which is poised to grow the cell line development market in the foreseen future. Moreover, the growing interest of key academic organizations and pharmaceutical companies in conducting a wide range of experiments further contributes to the significant growth in the market.

Market Restraints

Despite the significant growth, the cell line development market faces several market restraints that restrict the market progress. One of the significant growth restrictions includes complex regulatory guidelines and high initial investment. In addition, pharmaceutical companies require skilled personnel who hold expertise in handling advanced equipment for the isolation, characterization, and purification of cell lines. Challenges associated with reproducibility and the requirement of licensing agreements to set up advanced laboratories for the manufacturing of cell lines may impede the cell line development market growth. Cell line culturing laboratories also require regular maintenance that further enhances the overall cost of implementing the cell line development systems.

Growth Factors

Several growth factors that will drive cell line development in the future include growing demand for personalized medicines and rising research activities to develop innovative drugs to treat chronic diseases. The cell line development market is receiving funding support and collaborations between key industrial leaders, which is anticipated to become a prime growth factor propelling the market. Moreover, the growing demand for cell lines to study different diseases at the molecular and cellular levels is supporting this domain to achieve steady growth in the future.

Cell Line Development Market Segments

Based on distribution by source of cell lines / expression system, the cell line development market is segmented into mammalian, microbial, insect, and others.

  • Based on the source of cell lines / expression systems, mammalian cells will dominate the market and are poised to capture 74% of the overall revenue share in 2023.
  • Mammalian cells will likely grow at a higher CAGR of 13.4% during the forecast period.

Based on the application of cell lines, the cell line development market is segmented into research and development and biomanufacturing.

  • Based on the application of cell lines, biomanufacturing applications will dominate the market, and they are anticipated to hold a significant share (88%) in 2023.
  • Biomanufacturing segments will grow the cell line development market, and it is estimated to grow at a higher CAGR of 14.5% during 2023-2035

Based on the company size, the cell line development market is segmented into very large, large, mid-sized, and small.

  • Based on the company size, the mid-sized companies will dominate the cell line development market and are poised to capture 39% of the overall revenue share in 2023.
  • Mid-sized companies have shown significant potential to drive the market in the future, and it is estimated to grow at a higher CAGR of 13.7% during 2023-2035.

Based on the key geographical region, the cell line development market is segmented into North America (U.S., Canada, Mexico), Europe (France, Germany, Italy, Spain, UK, Russia, Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, Thailand, Malaysia, Indonesia, Rest of Asia-Pacific) and LAMEA (Brazil, South Africa, Saudi Arabia, UAE, Argentina, Rest of LAMEA)

  • Based on the geographical region, Europe will dominate the cell line development market, holding a significant 32% of the market share in 2023.
  • In Europe, the cell line development market will likely grow at a higher compounded annual growth rate (CAGR) of 13.8% during the forecast period.

Key Companies Profiled

The cell line development market report also includes detailed profiles of key players (listed below) that provide cell line development services solutions.

  • Biovian
  • Charles River Laboratories
  • Creative Biogene
  • FUJIFILM Diosynth Biotechnologies
  • KBI Biopharma
  • Lonza
  • ProBioGen
  • Syngene International
  • Thermo Fisher Scientific
  • WuXi Biologics

You Can Download Free Sample PDF Copy of This Report At:
https://www.rootsanalysis.com/reports/cell-line-development-market/request-sample.html

About Roots Analysis

Roots Analysis is a global leader in the pharma/biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists, and strategic investors for over a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research/consulting services dedicated to serving our clients in the best possible way.

Contact US
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com

MEDIA CITATIONS

  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry